RxDoctor Payments Data

Rebecca Olaughlin

Family · Forest Hill, MDNPI 1225766835

Payments from drug & device makers

$3,169in general payments, 2019–2025

Across 143 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$711
  • Amgen$582
  • Lilly USA, LLC$444
  • Exact Sciences$227
  • Boehringer Ingelheim$199
  • Silk Road Medical, Inc.$178
  • plus $829 from 13 others

What the payments were for

  • Food & beverage$3,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,169 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$69,516
Medicare patients
314
Services billed
1,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$34,130
TrulicityDulaglutide16$31,232
JanuviaSitagliptin Phosphate23$25,954
JardianceEmpagliflozin20$24,855
Nurtec OdtRimegepant Sulfate12$13,671
EliquisApixaban11$11,012
CreonLipase/Protease/Amylase12$8,538
Duloxetine Hcl20$3,643
Gabapentin62$1,931
Albuterol Sulfate HfaAlbuterol Sulfate55$1,511
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,389
Atorvastatin Calcium96$1,116
Metoprolol Succinate40$998
Omeprazole46$715
Levothyroxine Sodium57$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$34,13020 claims
Lilly USA, LLCTrulicity$444$31,23216 claims
MerckJanuvia$61$25,95423 claims
Boehringer IngelheimJardiance$199$24,85520 claims
PfizerNurtec Odt, Eliquis$149$24,68323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Forest Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →